Cooperative Agreement U01FD007352
Award Date
8/1/21
Completion Date
7/31/23
Dollars Obligated
$1.5M
Funding Federal Agency
Center for Drug Evaluation and Research
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Cooperative Agreement
Place of Performance
Florida, USA
Similar Awards
This $300,000 Cooperative Agreement awarded by the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) aims to develop physiologically-based pharmacokinetic (PBPK) model-based mechanistic in vitro-in vivo correlations (IVIVC) for long-acting injectable (LAI) drug product suspensions. The project seeks to comprehensively investigate the relationships between the formulation critical quality attributes (CQAs)...
The U.S. Food and Drug Administration (FDA) awarded a $249,485 Cooperative Agreement under the FDA Research program (CFDA 93.103) to Simulations Plus Inc. effective September 1, 2024 through August 31, 2027. The project aims to enhance the understanding of how food and gastric pH affect the release of drugs from amorphous solid dispersion (ASD) drug products, and how formulation and manufacturing variability impact in vivo performance. The project will generate in vitro dissolution data using...
The U.S. Food and Drug Administration (FDA) awarded a $1.45M Cooperative Agreement under the FDA Research program (CFDA 93.103) to the Academy of Managed Care Pharmacy to conduct a study titled "Bridging the Gap: Using Foreign Real-World Data to Inform Interchangeable Biosimilar Approvals." The project aims to evaluate the feasibility and validity of using real-world data from the U.S., Italy, and Denmark to emulate a biosimilar interchangeability (switching) study. The results will be...
The U.S. Food and Drug Administration (FDA) awarded a Cooperative Agreement under the FDA Research program (CFDA 93.103) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, for $298,422. The award, effective September 1, 2024 through August 31, 2027, aims to develop a semi-automated surveillance system using tree-based scan statistics to evaluate the safety and effectiveness of generic drug-device combinations compared to brand-name products. The...
This Cooperative Agreement award, provided by the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) under the Food and Drug Administration Research program (CFDA 93.103), supports Duke University's efforts to collaborate with the FDA on critical public health topics related to the agency's oversight of medical products, policies, and surveillance systems. The $700,000 award, with a performance period from September 2024 to August 2029, will enable Duke...
The University of Texas at Austin (UT Austin) received a $598,728 Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) to develop a physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro-in vivo correlation (IVIVC) for poly(lactide-co-glycolide) (PLGA) implants. The goal is to understand the critical formulation parameters affecting the in vitro and in vivo performance of long-acting PLGA-based buprenorphine...
This $499,774 cooperative agreement from the Department of Health and Human Services' Food and Drug Administration will support the University of California, San Diego in qualifying composite quantitative imaging biomarkers for diagnostic enrichment in nonalcoholic steatohepatitis (NASH) clinical trials. Over the one-year period from September 1, 2022 to August 31, 2023, UC San Diego will prepare and submit a biomarker qualification plan to the FDA's Center for Drug Evaluation and Research...
This Project Grant award, funded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), aims to develop innovative strategies to improve the biodistribution and pharmacokinetics of small molecule drugs. The $372,582 award, effective September 1, 2024, supports the University of Miami in pursuing two novel approaches: 1) designing albumin-binding targeted prodrugs that leverage endogenous albumin as a drug...
The National Institute of General Medical Sciences (NIGMS) awarded a $402,500 Project Grant under the Biomedical Research and Research Training Program (CFDA 93.859) to the University of Connecticut (UConn) for a research project titled "Enabling Oral Drug Formulations: Mechanistic Studies and Modeling". The project aims to systematically evaluate two key processes that influence oral drug absorption - the particle drifting effect and de-supersaturation kinetics - in order to develop...
This Cooperative Agreement award from the U.S. Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $249,826 to The Critical Path Institute (C-Path) to conduct psychometric analyses and prepare a quantitative study report to support the qualification of the Chronic Heart Failure Symptom Scale (CHF-SS) as a clinical outcome assessment tool for use in heart failure drug development. The project aims to finalize the statistical analysis plan, analyze the...